Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07090122 · ClinicalTrials.gov registry record · NA
Radiofrequency Ablation/Bone Augmentation + Radiotherapy vs Radiotherapy Alone
A NA study of Spine Metastases and Bone Pain, sponsored by University of Minnesota.
- Recruiting
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT07090122: Recruiting NA study of Spine Metastases and Bone Pain, sponsored by University of Minnesota.
NCT07090122 is a NA study of Spine Metastases and Bone Pain that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 36 participants, below the 488-participant average among 7 other Spine Metastases trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07090122, a NA study of Spine Metastases and Bone Pain, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, randomized controlled pilot study of radiofrequency ablation and bone augmentation (RFA/BA) plus radiotherapy (RT) vs. RT alone in patients with metastatic T5-L5 disease of the spine. Patients will be randomized 2:1 to receive either one treatment of RFA/BA plus RT or RT to evaluate the occurrence of skeletal-related events. Skeletal-related events (SREs) are defined as new clinical or radiologic evidence of pathologic fracture, spinal cord or nerve root compression, pain or instability, and/or necessity for additional local intervention (i.e. surgery, repeat RFA/BA or RT) due to persistent or progressive symptoms. Post-treatment follow-up for SREs are assessed at 1, 3, 6, 12, and 24 months.
Primary Outcome
Skeletal-related events are defined as new clinical or radiologic evidence of pathologic fracture, spinal cord or nerve root compression, pain or instability, and/or necessity for additional local intervention (i.e. surgery, repeat RFA/BA or RT) due to persistent or progressive symptoms.
Conditions Studied
Interventions
- PROCEDURE Radiofrequency ablation and bone augmentation with radiotherapy
- PROCEDURE Radiotherapy alone
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2028-06-13 |
| Phase | NA |
What NCT07090122 shows while recruiting
NCT07090122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 488-participant average among 7 other Spine Metastases trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Spine Metastases appearing as the primary indexed condition, and to 2 interventions - of which Radiofrequency ablation and bone augmentation with radiotherapy is the first listed.
NCT07090122 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07090122 about?
NCT07090122 is a clinical study titled "Radiofrequency Ablation/Bone Augmentation + Radiotherapy vs Radiotherapy Alone". This is a single-center, randomized controlled pilot study of radiofrequency ablation and bone augmentation (RFA/BA) plus radiotherapy (RT) vs. RT alone in patients with metastatic T5-L5 disease of the spine. Patients will be randomized 2:1 to receive either one treatment of RFA/BA plus RT or RT to ...
What is the current status of trial NCT07090122?
This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2025-12-01. Estimated completion is 2028-06-13.
What conditions does trial NCT07090122 study?
This clinical trial studies the following conditions: Spine Metastases, Bone Pain.
What interventions are being tested in trial NCT07090122?
The interventions under investigation include: Radiofrequency ablation and bone augmentation with radiotherapy (PROCEDURE), Radiotherapy alone (PROCEDURE).
Who is sponsoring clinical trial NCT07090122?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07090122 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spine Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
RECRUITING · NA
-
Dose-Escalated Spine SbRT for Localized Metastasis to the Spinal Column
RECRUITING · NA
-
Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation
ACTIVE NOT RECRUITING · NA
-
Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease
RECRUITING · Phase 1
-
Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI